The Sci-tech Innovation Board opened in July 2019, and it has been more than two years since then. According to data from the Shanghai Stock Exchange, as of July 22, there were 313 listed companies on the Science and Technology Innovation Board, with a total market value of 4.95 trillion yuan, and IPO funds raised over 380 billion yuan. As a sunrise industry, the field of medical devices is rising rapidly. Statistics from the Zhongcheng Medical Devices big data platform show that as of July 22, there are 38 medical device companies listed on the Science and Technology Innovation Board, accounting for 12.1% of the number.

　　 The enthusiasm for listing on the IVD enterprise science and technology board is high

　　 After the outbreak of the new crown pneumonia, the demand for in vitro diagnostic (IVD) reagent products has surged, and the in vitro diagnostic industry has developed rapidly with unprecedented momentum. IVD companies have become the "main force" of medical device companies "landing" on the science and technology innovation board. Statistics from the Zhongcheng Medical Devices big data platform show that from the perspective of medical device segmentation, the IVD field has the largest number of listed companies on the Science and Technology Innovation Board, with 16 companies accounting for 42.1%.

　　The revenue growth of listed companies is one of the indicators that best reflects the market dividend. In 2020, among the top five annual revenues of 38 medical device companies listed on the Science and Technology Innovation Board, there are 3 IVD companies. Among them, Shengxiang Biology and Oriental Biology rank first and second. The company's annual report shows that Shengxiang Bio's revenue increased by 1203.53% year-on-year, and its net profit increased by 6527.9% year-on-year.

　　Recently, Hotview Bio has recreated a performance myth with a pre-increased net profit of up to 800 times. The announcement from Hotview Biology shows that thanks to the explosive growth of the company's foreign trade orders, the net profit attributable to the parent in the first half of 2021 is expected to be 1.38 billion to 1.60 billion yuan, a year-on-year increase of 70546.05% to 81808.47%.

　　The stock price welcomes the "high rise theme"

　　 In the two years since the opening of the Science and Technology Innovation Board, medical device companies have demonstrated the vitality of the industry's development with a "rising trend" in stock prices.

　　 Statistics from the Zhongcheng medical device big data platform show that since the opening of the Science and Technology Innovation Board, 37 of the 38 listed medical device companies have seen their share prices rise to varying degrees, with an average increase of nearly 300%. Xinmai Medical and Nanwei Medical, as the first two medical device companies to be listed on the Sci-tech Innovation Board, immediately became "100-yuan shares" on the first day of listing.

It is worth noting that as of July 22, among the 37 companies mentioned above, 27 companies had a share price increase of over 100%; 8 companies had a share price increase of over 500%, namely Nawei Technology, Bairen Medical, Aibo Medical, Oriental Biology, Xinmai Medical, Haier Biology, Huaxi Biology and Huitai Medical, involving IVD, medical aesthetics and cardiovascular and other fields. Among them, the highest growth rate was nano and micro technology in the IVD field, which exceeded 1188%. According to the data, Nanomicro Technology is a high-tech enterprise engaged in the preparation and application of high-performance microspheres. It is currently one of the few companies in the world that can simultaneously prepare inorganic and organic high-performance nano-microsphere materials on a large scale. Its independent research and development The preparation technology and products of monodisperse silica gel microspheres, monodisperse polymer microspheres and chiral chromatography fillers broke the long-term monopoly pattern of foreign companies in the domestic market and filled the domestic gap. Except for Nanomicro Technology, the other 7 companies are industry leaders, and their share prices have naturally risen.

　　 It is worth noting that, as a subsidiary of the home appliance giant Haier Group's cross-border pharmaceutical industry, Haier Biotech's share price has risen among the top. In terms of scientific and technological innovation, Haier Bio's biomedical cryogenic technology broke the technical barriers of foreign countries and won the National Science and Technology Progress Award for its technology. At present, the company focuses on its technological ecological strategy, innovates and integrates low-temperature storage and Internet of Things technology, and continues to lead the market in four application scenarios such as biobanks, drug and reagent safety, blood safety, and vaccine safety.

　　Medical Beauty Circuit "Two Heavens of Ice and Fire"

　　 From the perspective of market value, as of July 22, the total market value of the 38 listed medical device companies on the Sci-tech Innovation Board reached 710.246 billion yuan, accounting for 14.35% of the Sci-tech Innovation Board; the average market value was 18.69 billion yuan. There were 13 medical device companies with a market value of over 20 billion yuan, an increase of 11 year-on-year. Among them, Huaxi Biosciences has a market value of 143.76 billion yuan, ranking first among 38 medical device companies listed on the Science and Technology Innovation Board, and ranks fourth in the market value of the Science and Technology Innovation Board, second only to SMIC, Kingsoft Office and Kangsino Bio.

　　 For a long time, the medical beauty industry has been recognized as a “gold-absorbing” track in the industry. As one of the leading hyaluronic acid companies in China, Huaxi Biotech has an industry advantage with a high coverage of hyaluronic acid raw materials business. It is understood that 36% of the raw materials of hyaluronic acid in the global market come from Huaxi Biotechnology. In addition, Huaxi Bio's complete cosmetics industry chain is also an important factor in promoting its rapid development. The "Forbidden City lipstick" launched in 2019 was very popular, and word-of-mouth and user stickiness have been greatly improved, which directly promoted the rise of the company's market value.

　　 However, Hao Hai Shengke, which is also on the medical beauty circuit, does not perform well in terms of market value. Since its listing on the Science and Technology Innovation Board, Haohaishengke has been in a state of falling stock prices for a long time. In the same period last year, it became the only medical device company whose share price fell on the Science and Technology Innovation Board with a 10% drop since its listing.

　　 From the perspective of annual performance, the two leading companies, Haohaishengke and Huaxi Biology, which belong to the same medical beauty track, also performed differently. The annual report shows that Haohai Biotech’s 2020 revenue was 1.332 billion yuan, a year-on-year decrease of 16.95%, and its net profit was 226 million yuan, a year-on-year decrease of 39.86%; Huaxi Biology’s 2020 revenue was 2.633 billion yuan, a year-on-year increase of 39.63%, net profit 646 million yuan, a year-on-year increase of 10.29%, becoming the third in 2020 revenue of medical device companies listed on the Science and Technology Innovation Board.

　　 However, benefiting from economic recovery and other factors, Haohaishengke also ushered in the first significant increase in performance after listing on the Science and Technology Innovation Board in the first half of this year. Haohaishengke’s 2021 semi-annual performance forecast shows that it is expected to achieve a net profit of 220 million to 250 million yuan in the first half of 2021, an increase of 192 million to 222 million yuan compared with the same period of the previous year, a year-on-year increase of 699.21% to 808.19%. ; The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be 210 million to 240 million yuan, an increase of 202 million to 232 million yuan year-on-year, and a year-on-year increase of 2582.03% to 2965.17%. On the day of the announcement, Haohaishengke achieved its daily limit with a 20% increase.

　　 In addition, what is different from previous years is that this year there has been a significant increase in the number of companies that intend to list on the initiative to withdraw their listing application materials, which has become a new phenomenon in 2021. For example, companies such as Dana Bio, Henglun Medical, Sunwo Medical, and Aopu Biotech have all withdrawn from the Science and Technology Innovation Board and terminated their IPOs. Many of these companies have suffered a significant decline in performance due to the impact of the new crown pneumonia epidemic, resulting in companies that do not meet the listing standards; concerns about market sales models have also become one of the factors for companies to terminate their listings.

　　 Generally speaking, in the two years since the opening of the Sci-tech Innovation Board, listed medical device companies have seen bright spots in both technological innovation and operating income, and many industry leaders have gathered. As the economy picks up, the number of medical device companies listed on the Sci-tech Innovation Board is expected to further increase.